PharmaNutra SpAMIL:PHN +0.57%85 Interest Coverage is 39.02 as of Mar. 2026, which is 71% below its 10-year median of 136.84. GuruFocus rates MIL:PHN with a GF Score™ of 85/100 and a GF Value™ of €71.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, PharmaNutra SpA ranks better than 71.82% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. PharmaNutra SpA's
Operating Income
for the
three
months ended in Mar. 2026 was €5.3 Mil. PharmaNutra SpA's Interest Expense for the
three
months ended in Mar. 2026 was €-0.1 Mil.
PharmaNutra SpA's interest coverage for the quarter that ended in Mar. 2026 was 39.02.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for PharmaNutra SpA's Interest Coverage or its related term are showing as below:
MIL:PHN'
s Interest Coverage Range Over the Past 10 Years
Min: 26.45 Med: 136.84 Max: 1007.53
Current: 52.28
MIL:PHN's Interest Coverage is ranked better than 71.82% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs MIL:PHN: 52.28
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
PharmaNutra SpA Interest Coverage Related Terms
PharmaNutra SpA Interest Coverage Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MIL:PHN vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (MIL:PHN) has a Interest Coverage of 39.02 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaNutra SpA and its competitors. This is 71% below median its historical median of 136.84. Over the past decade, PharmaNutra SpA's Interest Coverage has ranged from 26.45 to 1,007.53. According to the industry distribution chart, PharmaNutra SpA ranks #193 out of 685 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is PharmaNutra SpA's Interest Coverage too high?
PharmaNutra SpA's current Interest Coverage of 39.02 is 71% below median its 10-year median of 136.84. Over the past 10 years, this metric has ranged from a low of 26.45 to a high of 1,007.53. The Drug Manufacturers industry median Interest Coverage is 12.78. PharmaNutra SpA's value of 39.02 is 205.3% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #193 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PharmaNutra SpA has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #193 out of 685 companies for Interest Coverage. This puts PharmaNutra SpA in the upper half of its industry. The industry median Interest Coverage is 12.78. PharmaNutra SpA's value of 39.02 is 205.3% above this benchmark. Historically, PharmaNutra SpA's own Interest Coverage has ranged from 26.45 to 1,007.53 over the past decade. While the company's 10-year median is 136.84 vs. the industry median of 12.78, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current Interest Coverage of 39.02 is 205.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current Interest Coverage is 39.02, which is 71% below median its own 10-year median of 136.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €71.41, compared to a current price of €87.70 — trading 22.8% above its estimated fair value. The current Interest Coverage is 39.02, which is 71% below median its 10-year median of 136.84 and 205.3% above the Drug Manufacturers industry median of 12.78. PharmaNutra SpA's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current Interest Coverage is 39.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €87.70 is trading 22.8% above its estimated GF Value™ of €71.41.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
Interest Coverage: 39.02 (71% below median its 10-year median of 136.84)
GF Value™: €71.41 vs. price of €87.70 (22.8% above fair value)
Industry Position: 205.3% above the Drug Manufacturers median (#193 of 685)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
85GF Score
Get the complete analysis for MIL:PHN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
